Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a peptide involved in physio-pathological processes of the eye. It exerts multiple effects directly through activation of its related receptors and indirectly through increases in the synthesis of activity-dependent neuroprotective protein (ADNP). To study the role of ADNP and protect against ADNP deficiencies, a small peptide called NAP was synthetized. It includes an eight amino acid active site sequence of ADNP. In this review, we summarize the knowledge regarding the neuroprotective function played by PACAP and NAP in retinal tissue and provide an overview of the correlation between PACAP and ADNP in the context of diabetic retinopathy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arimura A (1998) Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn J Physiol 48:301–331. https://doi.org/10.2170/jjphysiol.48.301
Arimura A, Shioda S (1995) Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front Neuroendocrinol 16:53–88. https://doi.org/10.1006/frne.1995.1003
Ashur-Fabian O, Giladi E, Brenneman DE, Gozes I (1997) Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. J Mol Neurosci 9(3):211–222. https://doi.org/10.1007/BF02800503
Atlasz T, Babai N, Kiss P, Reglodi D, Tamás A, Szabadfi K, Tóth G, Hegyi O, Lubics A, Gábriel R (2007) Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. Gen Comp Endocrinol 153(1–3):108–114. https://doi.org/10.1016/j.ygcen.2006.12.022
Atlasz T, Szabadfi K, Kiss P, Babai N, Koszegi Z, Tamas A, Reglodi D, Gabriel R (2008) PACAP-mediated neuroprotection of neurochemically identified cell types in MSG-induced retinal degeneration. J Mol Neurosci 36:97–104. https://doi.org/10.1007/s12031-008-9059-5
Atlasz T, Szabadfi K, Kiss P, Marton Z, Griecs M, Hamza L, Gaal V, Biro Z, Tamas A, Hild G, Nyitrai M, Toth G, Reglodi D, Gabriel R (2011) Effects of PACAP in UV-A radiation-induced retinal degeneration models in rats. J Mol Neurosci 43:51–57. https://doi.org/10.1007/s12031-010-9392-3
Atlasz T, Szabadfi K, Kiss P, Racz B, Gallyas F, Tamas A, Gaal V, Marton Z, Gabriel R, Reglodi D (2010) Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects. Ann N Y Acad Sci 1200:128–139
Atlasz T, Szabadfi K, Kiss P, Tamas A, Toth G, Reglodi D, Gabriel R (2010) Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res Bull 81(4–5):497–504
Atlasz T, Szabadfi K, Reglodi D, Kiss P, Tamas A, Tóth G, Molnár A, Szabó K, Gábriel R (2009) Effects of pituitary adenylate cyclase activating polypeptide and its fragments on retinal degeneration induced by neonatal monosodium glutamate treatment. Ann N Y Acad Sci 1163:348–352. https://doi.org/10.1111/j.1749-6632.2008.03650.x
Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE, Gozes I (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72:1283–1293. https://doi.org/10.1046/j.1471-4159.1999.0721283.x
Belokopytov M, Shulman S, Dubinsky G, Gozes I, Belkin M, Rozner M (2011) Ameliorative effect of NAP on laser-induced retinal damage. Ameliorative effect of NAP on laser-induced retinal damage. Acta Ophthalmol 89(2):e126–31. https://doi.org/10.1111/j.1755-3768.2010.02041.x
Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, Eizenberg O, Trembolver V, Shohami E (2001) A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther 296(1):57–63
Blechman J, Levkowitz G (2013) Alternative splicing of the pituitary adenylate cyclase-activating polypeptide receptor PAC1: mechanisms of fine tuning of brain activity. Front Endocrinol (Lausanne) 4:55. https://doi.org/10.3389/fendo.2013.00055
Borba J, Pereira Henze I, Silveira M, Cussa Kubrusly R, Gardino P, Fialho de Mello MC, Hokoç JN, Garcia de Mello F (2005) Pituitary adenylate cyclase-activating polypeptide (PACAP) can act as determinant of the tyrosine hydroxylase phenotype of dopaminergic cells during retina development. Brain Res Dev Brain Res 156(2):193–201. https://doi.org/10.1016/j.devbrainres.2005.02.016
Bringmann A, Reichenbach A (2001) Role of Muller cells in retinal degenerations. Front Biosci 6:E72-92
Canonico PL, Copani A, D’Agata V, Musco S, Petralia S, Travali S, Stivala F, Cavallaro S (1996) Activation of pituitary adenylate cyclase-activating polypeptide receptors prevents apoptotic cell death in cultured cerebellar granule cells. Ann N Y Acad Sci 805:470–472. https://doi.org/10.1111/j.1749-6632.1996.tb17505.x
Castorina A, Scuderi S, D'Amico AG, Drago F, D'Agata V (2014) PACAP and VIP increase the expression of myelin-related proteins in rat schwannoma cells: involvement of PAC1/VPAC2 receptor-mediated activation of PI3K/Akt signaling pathways. Exp Cell Res. 322(1):108–21. https://doi.org/10.1016/j.yexcr.2013.11.003
Cavallaro S, D’Agata V, Drago F, Musco S, Nuciforo G, Ricciardolo F, Tracali S, Sticala F, Arimura A, Canonico PL (1996) Ocular expression of type-1 pituitary adenylate cyclase-activating polypeptide (PACAP) receptors. Ann N Y Acad Sci 26(805):555–557. https://doi.org/10.1111/j.1749-6632.1996.tb17518.x (PMID: 8993438)
D’Alessandro A, Cervia D, Catalani E, Gevi F, Zolla L, Casini G (2014) Protective effects of the neuropeptides PACAP, substance P and the somatostatin analogue octreotide in retinal ischemia: a metabolomic analysis. Mol Biosyst 10(6):1290–1304. https://doi.org/10.1039/c3mb70362b
D’Amico AG, Maugeri G, Bucolo C, Saccone S, Federico C, Cavallaro S, D’Agata V (2017) NAP interferes with hypoxia-inducible factors and VEGF expression in retina of diabetic rats. J Mol Neurosci 61:256–266. https://doi.org/10.1007/s12031-016-0869-6
D’Amico AG, Maugeri G, Rasà D, Federico C, Saccone S, Lazzara F, Fidilio A, Drago F, Bucolo C, D’Agata V (2019) NAP modulates hyperglycemic-inflammatory event of diabetic retina by counteracting outer blood retinal barrier damage. J Cell Physiol 234(4):5230–5240. https://doi.org/10.1002/jcp.27331
D’Amico AG, Maugeri G, Rasà DM, La Cognata V, Saccone S, Federico C, Cavallaro S, D’Agata V (2018) NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression. J Cell Physiol 233(2):1120–1128. https://doi.org/10.1002/jcp.25971
D’Amico AG, Maugeri G, Reitano R, Bucolo C, Saccone S, Drago F, D’Agata V (2015) PACAP modulates expression of hypoxia-inducible factors in streptozotocin-induced diabetic rat retina. J Mol Neurosci 57(4):501–509. https://doi.org/10.1007/s12031-015-0621-7
D’Agata V, Cavallaro S (1998) Functional and molecular expression of PACAP/VIP receptors in the rat retina. Mol Brain Res 54:161–164. https://doi.org/10.1016/s0169-328x(97)00335-5
D’Amico AG, Maugeri G, Rasà DM, Bucolo C, Saccone S, Federico C, Cavallaro S, D’Agata V (2017) Modulation of IL-1β and VEGF expression in rat diabetic retinopathy after PACAP administration. Peptides 97:64–69. https://doi.org/10.1016/j.peptides.2017.09.014 (PMID: 28964802)
Danyadi B, Szabadfi K, Reglodi D, Mihalik A, Danyadi T, Kovacs Z, Batai I, Tamas A, Kiss P, Toth G, Gabriel R (2014) PACAP application improves functional outcome of chronic retinal ischemic injury in rats-evidence from electroretinographic measurements. J Mol Neurosci 54:293–299. https://doi.org/10.1007/s12031-014-0296-5
Divinski I, Mittelman L, Gozes I (2004) A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279:28531–28538. https://doi.org/10.1074/jbc.M403197200
Fabian E, Reglodi D, Horvath G, Opper B, Toth G, Fazakas C, Vegh AG, Wilhelm I, Krizbai IA (2019) Pituitary adenylate cyclase activating polypeptide acts against neovascularization in retinal pigment epithelial cells Ann N Y Acad Sci 1455(1):160–172. https://doi.org/10.1111/nyas.14189
Fabian E, Reglodi D, Mester L, Szabo A, Szabadfi K, Tamas A, Toth G, Kovacs K (2012) Effects of PACAP on intracellular signaling pathways in human retinal pigment epithelial cells exposed to oxidative stress. J Mol Neurosci 48(3):493–500. https://doi.org/10.1007/s12031-012-9812-7
Gábriel R (2013) Neuropeptides and diabetic retinopathy. Br J Clin Pharmacol 75(5):1189–1201. https://doi.org/10.1111/bcp.12003
Gábriel R, Pöstyéni E, Dénes V (2019) Neuroprotective potential of pituitary adenylate cyclase activating polypeptide in retinal degenerations of metabolic origin. Front Neurosci 13:1031. https://doi.org/10.3389/fnins.2019.01031
Gastinger MJ, Singh RS, Barber AJ (2006) Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 47:3143–3150. https://doi.org/10.1167/iovs.05-1376
Ghatei MA, Takahashi K, Suzuki Y, Gardiner J, Jones PM, Bloom SR (1993) Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol 136:159–166. https://doi.org/10.1677/joe.0.1360159
Girard BM, Campbell SE, Beca KI, Perkins M, Hsiang H, May V, Vizzard MA (2020) Intrabladder PAC1 Receptor Antagonist, PACAP(6–38), Reduces Urinary Bladder Frequency and Pelvic Sensitivity in Mice Exposed to Repeated Variate Stress (RVS). J Mol Neurosci. https://doi.org/10.1007/s12031-020-01649-x
Giunta S, Castorina A, Adorno A, Mazzone V, Carnazza ML, D’Agata V (2010) PACAP and VIP affect NF1 expression in rat malignant peripheral nerve sheath tumor (MPNST) cells. Neuropeptides 44(1):45–51. https://doi.org/10.1016/j.npep.2009.10.003
Giunta S, Castorina A, Bucolo C, Magro G, Drago F, D’Agata V (2012) Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats. Peptides 37:32–39. https://doi.org/10.1016/j.peptides.2012.06.004
Gozes I (2020) The ADNP syndrome and CP201 (NAP) potential and hope. Neurol, Front. https://doi.org/10.3389/fneur.2020.608444
Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S, Brenneman DE (2002) NAP accelerates the performance of normal rats in the water maze. J Mol Neurosci 1–2:167–170. https://doi.org/10.1007/s12031-002-0028-0
Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, Perl O, Glazner GW, Brenneman DE (1999) A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. Ann N Y Acad Sci 897:125–35. https://doi.org/10.1111/j.1749-6632.1999.tb07884.x
Gozes I, Divinski I, Piltzer I (2008) NAP and D-SAL: neuroprotection against the beta amyloid peptide (1–42) BMC Neurosci 9. Suppl 3(Suppl 3):S3. https://doi.org/10.1186/1471-2202-9-S3-S3
Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD (2003) From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci 20(3):315–322. https://doi.org/10.1385/JMN:20:3:315
Gozes I, Ivashko-Pachima Y (2015) ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. Front Aging Neurosci 7:205. https://doi.org/10.3389/fnagi.2015.00205
Gozes I, Ivashko-Pachima Y, Kapitansky O, Sayas CL, Iram T (2019) Single-cell analysis of cytoskeleton dynamics: From isoelectric focusing to live cell imaging and RNA-seq. J Neurosci Methods 323:119–124. https://doi.org/10.1016/j.jneumeth.2019.05.014
Gozes I, Ivashko-Pachima Y, Sayas CL (2018) ADNP, a microtubule interacting protein, provides neuroprotection through end binding proteins and Tau: an amplifier effect. Front Mol Neurosci 11:151. https://doi.org/10.3389/fnmol.2018.00151
Grigg I, Ivashko-Pachima Y, Hait TA, Korenková V, Touloumi O, Lagoudaki R, Van Dijck A, Marusic Z, Anicic M, Vukovic J, Kooy RF, Grigoriadis N, Gozes I (2020) Tauopathy in the young autistic brain: novel biomarker and therapeutic target. Transl Psychiatry 10(1):228. https://doi.org/10.1038/s41398-020-00904-4
Hannibal J (2002) Neurotransmitters of the retino-hypothalamic tract. Cell Tissue Res 309(1):73–88. https://doi.org/10.1007/s00441-002-0574-3
Hannibal J, Ding JM, Chen D, Fahrenkrug J, Larsen PJ, Gillette MU, Mikkelsen JD (1997) Pituitary adenylate cyclase-activating peptide (PACAP) in the retinohypothalamic tract: a potential daytime regulator of the biological clock. J Neurosci 17(7):2637–2644. https://doi.org/10.1523/JNEUROSCI.17-07-02637
Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50(2):265–70
Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 166(1):4–17. https://doi.org/10.1111/j.1476-5381.2012.01871.x
Holopigian K, Greenstein VC, Seiple W, Hood DC, Carr RE (1997) Evidence for photoreceptor changes in patients with diabetic retinopathy Invest Ophthalmol Vis Sci 38(11):2355–2365
Hosoya M, Onda H, Ogi K, Masuda Y, Miyamoto Y, Ohtaki T, Okazaki H, Arimura A and Fujino M (1993) Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase-activating polypeptide (PACAP). Biochem Biophys Res Commun 15;194(1):133–43. https://doi.org/10.1006/bbrc.1993.1795
Idan-Feldman A, Schirer Y, Polyzoidou E, Touloumi O, Lagoudaki R, Grigoriadis NC, Gozes I (2011) Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis 44(3):327–339. https://doi.org/10.1016/j.nbd.2011.06.020
Ivashko-Pachima Y, Gozes I (2018) NAP protects against Tau hyperphosphorylation through GSK3. Curr Pharm Des 24(33):3868–3877. https://doi.org/10.2174/1381612824666181112105954
Ivashko-Pachima Y, Gozes I (2019) A novel microtubule-Tau association enhancer and neuroprotective drug candidate: Ac-SKIP. Front Cell Neurosci 13:435. https://doi.org/10.3389/fncel.2019.00435
Ivashko-Pachima Y, Gozes I (2020) Deciphering the enigma: NAP (CP201) the active ADNP drug candidate enters cells by dynamin-associated endocytosis. J Mol Neurosci 70(7):993–998. https://doi.org/10.1007/s12031-020-01632-6
Ivashko-Pachima Y, Hadar A, Grigg I, Korenková V, Kapitansky O, Karmon G, Gershovits M, Sayas CL, Kooy RF, Attems J, Gurwitz D, Gozes I (2019) Discovery of autism/intellectual disability somatic mutations in Alzheimer’s brains: mutated ADNP cytoskeletal impairments and repair as a case study. Mol Psychiatry. https://doi.org/10.1038/s41380-019-0563-5
Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I (2017) ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Mol Psychiatry 22(9):1335–1344. https://doi.org/10.1038/mp.2016.255
Jehle T, Dimitriu C, Auer S, Knoth R, Vidal-Sanz M, Gozes I, Lagrèze WA (2008) The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush. Graefes Arch Clin Exp Ophthalmol 246(9):1255–1263. https://doi.org/10.1007/s00417-007-0746-7ErratuminGraefesArchClinExpOphthalmol.2008Sep;246(9):1355
Józsa R, Somogyvári-Vigh A, Reglödi D, Hollósy T, Arimura A (2001) Distribution and daily variations of PACAP in the chicken brain. Peptides 22(9):1371–1377. https://doi.org/10.1016/s0196-9781(01)00477-6
Kapitansky O, Sragovich S, Jaljuli I, Hadar A, Giladi E, Gozes I (2020) Age and sex-dependent ADNP regulation of muscle gene expression is correlated with motor behavior: possible feedback mechanism with PACAP. Int J Mol Sci 21(18):6715. https://doi.org/10.3390/ijms21186715
Kovacs AK, Atlasz T, Werling D, Szabo E, Reglodi D, Toth GK (2020) Stability test of PACAP in eye drops. J Mol Neurosci. https://doi.org/10.1007/s12031-020-01532-9
Kovács-Valasek A, Szabadfi K, Dénes V, Szalontai B, Tamás A, Kiss P, Szabó A, Setalo G Jr, Reglődi D, Gábriel R (2017) Accelerated retinal aging in PACAP knock-out mice. Neuroscience 348:1–10. https://doi.org/10.1016/j.neuroscience.2017.02.003
Kvarik T, Mammel B, Reglodi D, Kovacs K, Werling D, Bede B, Vaczy A, Fabian E, Toth G, Kiss P, Tamas A, Ertl T, Gyarmati J, Atlasz T (2016) PACAP is protective in a rat model of retinopathy of prematurity. J Mol Neurosci 60(2):179–185. https://doi.org/10.1007/s12031-016-0797-5
Laburthe M, Couvineau A, Marie JC (2002) VPAC receptors for VIP and PACAP. Recept Channels 8(3–4):137–153
Lagrèze WA, Pielen A, Steingart R, Schlunck G, Hofmann H, Gozes I, Kirsch M (2005) The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci 46(3):933–938. https://doi.org/10.1167/iovs.04-0766
Lakk M, Denes V, Gabriel R (2015) Pituitary adenylate cyclase-activating polypeptide receptors signal via phospholipase C pathway to block apoptosis in newborn rat retinaneurochem Res 40(7):1402–1409. https://doi.org/10.1007/s11064-015-1607-0
Lakk M, Szabo B, Volgyi B, Gabriel R, Denes V (2012) Development-related splicing regulates pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in the retina. Invest Ophthalmol Vis Sci 53(12):7825–7832. https://doi.org/10.1167/iovs.12-10417
Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, Giladi E, Romano J, Gozes I (2002) NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 33:1085–1092
Li M, David C, Kikuta T, Somogyvari-Vig A, Arimura A (2005) Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38. J Mol Neurosci 27(1):91–105. https://doi.org/10.1385/JMN:27:1:091
Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, Harmar AJ (1993) The VIP receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334(1):3–8. https://doi.org/10.1016/0014-5793(93)81668-p
Martínez-Rojas VA, Jiménez-Garduño AM, Michelatti D, Tosatto L, Marchioretto M, Arosio D, Basso M, Pennuto M, Musio C (2020) ClC-2-like chloride current alterations in a cell model of spinal and bulbar muscular atrophy, a polyglutamine disease. J Mol Neurosci. https://doi.org/10.1007/s12031-020-01687-5
Maugeri G, D'Amico AG, Bucolo C, D'Agata V (2019b) Protective effect of PACAP-38 on retinal pigmented epithelium in an in vitro and in vivo model of diabetic retinopathy through EGFR-dependent mechanism. Peptides 119:170108. https://doi.org/10.1016/j.peptides.2019.170108
Maugeri G, D’Amico AG, Castrogiovanni P, Saccone S, Federico C, Reibaldi M, Russo A, Bonfiglio V, Avitabile T, Longo A, D’Agata V (2019) PACAP through EGFR transactivation preserves human corneal endothelial integrity. J Cell Biochem 120(6):10097–10105. https://doi.org/10.1002/jcb.28293
Maugeri G, D’Amico AG, Gagliano C, Saccone S, Federico C, Cavallaro S, D’Agata V (2017) VIP family members prevent outer blood retinal barrier damage in a model of diabetic macular edema. J Cell Physiol 232(5):1079–1085. https://doi.org/10.1002/jcp.25510
Maugeri G, D’Amico AG, Saccone S, Federico C, Cavallaro S, D’Agata V (2017) PACAP and VIP inhibit HIF-1α-mediated VEGF expression in a model of diabetic macular edema. J Cell Physiol 232(5):1209–1215. https://doi.org/10.1002/jcp.25616
Maugeri G, Longo A, D’Amico AG, Rasà DM, Reibaldi M, Russo A, Bonfiglio V, Avitabile T, D’Agata V (2018) Trophic effect of PACAP on human corneal endothelium. Peptides 99:20–26. https://doi.org/10.1016/j.peptides.2017.11.003
Mester L, Kovacs K, Racz B, Solti I, Atlasz T, Szabadfi K, Tamas A, Reglodi D (2011) Pituitary adenylate cyclase-activating polypeptide is protective against oxidative stress in human retinal pigment epithelial cells. J Mol Neurosci 43(1):35–43. https://doi.org/10.1007/s12031-010-9427-9
Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567–574
Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643–648
Moody TW, Lee L, Jensen RT (2020) The G protein-coupled receptor PAC1 regulates transactivation of the receptor tyrosine kinase HER3. J Mol Neurosci. https://doi.org/10.1007/s12031-020-01711-8
Morrow JA, Lutz EM, West KM, Fink G and Harmar AJ (1993) Molecular cloning and expression of a cDNA encoding a receptor for pituitary adenylate cyclaseactivating polypeptide (PACAP). FEBS Lett 329:99-105
Nakamachi T, Farkas J, Watanabe J, Ohtaki H, Dohi K, Arata S, Shioda S (2011) Role of PACAP in neural stem/progenitor cell and astrocyte–from neural development to neural repair. Curr Pharm 17(10):973–984. https://doi.org/10.2174/138161211795589346
Nakamachi T, Li M, Shioda S, Arimura A (2006) Signaling involved in pituitary adenylate cyclase-activating polypeptide-stimulated ADNP expression. Peptides 27(7):1859–1864. https://doi.org/10.1016/j.peptides.2006.01.007
Nakamachi T, Matkovits A, Seki T, Shioda S (2012) Front Endocrinol (Lausanne). Distribution and protective function of pituitary adenylate cyclase-activating polypeptide in the retina 3:145. https://doi.org/10.3389/fendo.2012.00145
Nakamachi T, Ohtaki H, Seki T, Yofu S, Kagami N, Hashimoto H, Shintani N, Baba A, Mark L, Lanekoff I, Kiss P, Farkas J, Reglodi D, Shioda S (2016) PACAP suppresses dry eye signs by stimulating tear secretion. Nat Commun 7:12034. https://doi.org/10.1038/ncomms12034
Nakamachi T, Ohtaki H, Yofu S, Dohi K, Watanabe J, Hayashi D, Matsuno R, Nonaka N, Itabashi K, Shioda S (2008) Pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) co-localizes with activity-dependent neuroprotective protein (ADNP) in the mouse brains. Regul Pept 145(1–3):88–95. https://doi.org/10.1016/j.regpep.2007.09.025
Nakatani M, Seki T, Shinohara Y, Taki C, Nishimura S, Takaki A, Shioda S (2006) Pituitary adenylate cyclase-activating peptide (PACAP) stimulates production of interleukin-6 in rat Müller cells. Peptides 27:1871–1876. https://doi.org/10.1016/j.peptides.2005.12.011
Njaine B, Martins RA, Santiago MF, Linden R, Silveira MS (2010) Pituitary adenylyl cyclase-activating polypeptide controls the proliferation of retinal progenitor cells through downregulation of cyclin D1. Eur J Neurosci 32(3):311–321. https://doi.org/10.1111/j.1460-9568.2010.07286.x
Ohtaki H, Nakamachi T, Dohi K, Shioda S (2008) Role of PACAP in ischemic neural death. J Mol Neurosci 36(1-3):16-25. https://doi.org/10.1007/s12031-008-9077-3
Onali P, Olianas MC (1994) PACAP is a potent and highly effective stimulator of adenylyl cyclase activity in the retinas of different mammalian species. Brain Res 641(1):132–134. https://doi.org/10.1016/0006-8993(94)91825-2
Oz S, Ivashko-Pachima Y, Gozes I (2012) The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS ONE 7(12):e51458. https://doi.org/10.1371/journal.pone.0051458
Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N, Rosin-Arbesfeld R, Mittelman L, Segev O, Hirsch JA, Gozes I (2014) The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol Psychiatry 19(10):1115–24. https://doi.org/10.1038/mp.2014.97
Pilzer I, Gozes I (2006) VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides 27(11):2867–2876. https://doi.org/10.1016/j.peptides.2006.06.007
Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, Servoss SJ, Brenneman DE, Gozes I (2003) Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 144(1):83–90. https://doi.org/10.1016/s0165-3806(03)00162-7
Pisegna JR and Wank SA (1993) Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci USA 1;90(13):6345–9. https://doi.org/10.1073/pnas.90.13.6345
Puro DG (2002) Diabetes-induced dysfunction of retinal Muller cells. Trans Am Ophthalmol 100:339–352
Racz B, Gallyas F Jr, Kiss P, Tamas A, Lubics A, Lengvari I, Roth E, Toth G, Hegyi O, Verzal Z, Fabricsek C, Reglodi D (2007) Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the PKA-Bad-14-3-3 signaling pathway in glutamate-induced retinal injury in neonatal rats. Neurotox Res 12(2):95–104. https://doi.org/10.1007/BF03033918
Rácz B, Gallyas F Jr, Kiss P, Tóth G, Hegyi O, Gasz B, Borsiczky B, Ferencz A, Roth E, Tamás A, Lengvári I, Lubics A, Reglodi D (2006) The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involves inhibition of proapoptotic signaling pathways. Regul Pept 137(1–2):20–26. https://doi.org/10.1016/j.regpep.2006.02.009
Rácz B, Tamás A, Kiss P, Tóth G, Gasz B, Borsiczky B, Ferencz A, Gallyas F Jr, Roth E, Reglodi D (2006) Involvement of ERK and CREB signaling pathways in the protective effect of PACAP in monosodium glutamate-induced retinal lesion. Ann N Y Acad Sci 1070:507–511. https://doi.org/10.1196/annals.1317.070
Reglodi D, Somogyvari-Vigh A, Vígh J, Li M, Lengvári I, Arimura A (2001) Pituitary adenylate cyclase activating polypeptide is highly abundant in the nervous system of the anoxia-tolerant turtle. Pseudemys scripta elegans Peptides 22(6):873–878. https://doi.org/10.1016/s0196-9781(01)00412-0
Scuderi S, D’Amico AG, Castorina A, Federico C, Marrazzo G, Drago F, Bucolo C, D’Agata V (2014) Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic death. J Mol Neurosci 54(3):395–404. https://doi.org/10.1007/s12031-014-0244-4
Scuderi S, D’Amico AG, Castorina A, Imbesi R, Carnazza ML, D’Agata V (2013) Ameliorative effect of PACAP and VIP against increased permeability in a model of outer blood retinal barrier dysfunction. Peptides 39:119–124. https://doi.org/10.1016/j.peptides.2012.11.015
Scuderi S, D’Amico AG, Federico C, Saccone S, Magro G, Bucolo C, Drago F, D’Agata V (2015) Different Retinal Expression Patterns of IL-1α, IL-1β, and Their Receptors in a Rat Model of Type 1 STZ-Induced Diabetes. J Mol Neurosci 56(2):431–439. https://doi.org/10.1007/s12031-015-0505-x
Segre GV, Goldring SR (1993) Receptors for secretin, calcitonin, parathyroid hormone PTH)/PTH-related peptide, glucagon-like peptide 1, growth hormonereleasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol Metab 4(10):309–314. https://doi.org/10.1016/1043-2760(93)90071-l
Seki T, Itoh H, Nakamachi T, Endo K, Wada Y, Nakamura K, Shioda S (2011) Suppression of rat retinal ganglion cell death by PACAP following transient ischemia induced by high intraocular pressure. J Mol Neurosci 43(1):30–4. https://doi.org/10.1007/s12031-010-9410-5
Seki T, Izumi S, Shioda S, Zhou CJ, Arimura A, Koide R (2000) Gene expression for PACAP receptor mRNA in the rat retina by in situ hybridization and in situ RT-PCR. Ann NY Acad Sci 921:366–369. https://doi.org/10.1111/j.1749-6632.2000.tb06995.x
Seki T, Shioda S, Ogino D, Nakai Y, Arimura A, Koide R (1997) Distribution and ultrastructural localization of a receptor for pituitary adenylate cyclase activating polypeptide and its mRNA in the rat retina. Neurosci Lett 238:127–130. https://doi.org/10.1016/s0304-3940(97)00869-0
Seki T, Shioda S, Izumi S, A. Arimura A, Koide R, (2000) Electron microscopic observation of pituitary adenylate cyclase activating polypeptide (PACAP)-containing neurons in the rat retina. Peptides 21(1):109–113. https://doi.org/10.1016/s0196-9781(99)00180-1
Seki T, Shioda S, Nakai Y, Arimura A, Koide R (1998) Distribution and ultrastructural localization of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor in the rat retina. Ann N Y Acad Sci 865:408–411. https://doi.org/10.1111/j.1749-6632.1998.tb11205.x
Shioda S, Ohtaki H, Nakamachi T, Dohi K, Watanabe J, Nakajo S, Arata S, Kitamura S, Okuda H, Takenoya F, Kitamura Y (2006) Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann. N.Y. Acad Sci 1070:550–560. https://doi.org/10.1196/annals.1317.080
Silveira MS, Costa MR, Bozza M, Linden R (2002) Pituitary adenylyl cyclase-activating polypeptide prevents induced cell death in retinal tissue through activation of cyclic AMP-dependent protein kinase. J Biol Chem 277:16075–16080. https://doi.org/10.1074/jbc.M110106200
Simó R, Villarroel M, Corraliza L, Hernández C, Garcia - Ramírez M (2010) The retinal pigment epithelium: Something more than a constituent of the blood - retinal - barrier - implications for the pathogenesis of diabetic retinopathy. Journal of Biomedicine and Biotechnology (2010) 190724–15. J Biomed Biotechnol 2010:190724. https://doi.org/10.1155/2010/190724
Solymar M, Ivic I, Balasko M, Fulop BD, Toth G, Tamas A, Reman G, Koller A, Reglodi D (2018) Pituitary adenylate cyclase-activating polypeptide ameliorates vascular dysfunction induced by hyperglycaemia. Diab Vasc Dis Res 15(4):277–285. https://doi.org/10.1177/1479164118757922
Somogyvari-Vigh A, Reglodi D (2004) Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr Pharm Des 10:2861–2889. https://doi.org/10.2174/1381612043383548
Sragovich S, Ziv Y, Vaisvaser S, Shomron N, Hendler T, Gozes I (2019) The autism-mutated ADNP plays a key role in stress response. Transl Psychiatry 9(1):235. https://doi.org/10.1038/s41398-019-0569-4
Svoboda M, Tastenoy M, Ciccarelli E, Stie venart M and Christophe J, (1993) Cloning of a splice variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I receptor. Biochem Biophys Res Commun 195(2):881–888. https://doi.org/10.1006/bbrc.1993.2127
Szabadfi K, Atlasz T, Kiss P, Reglodi D, Szabo A, Kovacs K, Szalontai B, Setalo GyJr, Banki E, Csanaky K, Tamas A, Gabriel R (2012) Protective effects of the neuropeptide PACAP in diabetic retinopathy. Cell Tissue Res 348(1):37–46. https://doi.org/10.1007/s00441-012-1349-0
Szabadfi K, Reglodi D, Szabo A, Szalontai B, Valasek A, Setalo G Jr, Kiss P, Tamas A, Wilhelm M, Gabriel R (2016) Pituitary adenylate cyclase activating polypeptide, a potential therapeutic agent for diabetic retinopathy in rats: focus on the vertical information processing pathway. Neurotox Res 29:432–446. https://doi.org/10.1007/s12640-015-9593-1
Szabadfi K, Szabo A, Kiss P, Reglodi D, Setalo GJr, Kovacs K, Tamas A, Toth G, Gabriel R, (2014) PACAP promotes neuron survival in early experimental diabetic retinopathy. Neurochem Int 64:84–91. https://doi.org/10.1016/j.neuint.2013.11.005
Szabo A, Danyadi B, Bognar E, Szabadfi K, Fabian E, Kiss P, Mester L, Manavalan S, Atlasz T, Gabriel R, Toth G, Tamas A, Reglodi D, Kovacs K (2012) Effect of PACAP on MAP kinases, Akt and cytokine expressions in rat retinal hypoperfusion. Neurosci Lett 523(2):93–98. https://doi.org/10.1016/j.neulet.2012.06.044
Toth D, Szabo E, Tamas A, Juhasz T, Horvath G, Fabian E, Opper B, Szabo D, Maugeri G, D’Amico AG, D’Agata V, Vicena V, Reglodi D (2020) Protective effects of PACAP in peripheral organs. Front Endocrinol Lausanne 11:377. https://doi.org/10.3389/fendo.2020.00377
Vaczy A, Reglodi D, Somoskeoy T, Kovacs K, Lokos E, Szabo E, Tamas A, Atlasz T (2016) The protective role of PAC1- receptor agonist maxadilan in BCCAO-induced retinal degeneration. J Mol Neurosci 60(2):186–194. https://doi.org/10.1007/s12031-016-0818-4
Varga B, Szabadfi K, Kiss P, Fabian E, Tamas A, Griecs M, Gabriel R, Reglodi D, Kemeny-Beke A, Pamer Z, Biro Z, TosakiA AT, Juhasz B (2011) PACAP improves functional outcome in excitotoxic retinal lesion: an electroretinographic study. J Mol Neurosci 43(1):44–50. https://doi.org/10.1007/s12031-010-9406-1
Vaudry D, Falluel-Morel A, Basille M, Pamantung TF, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ (2003) Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J Neurosci Res 72(3):303–316. https://doi.org/10.1002/jnr.10530
Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H (2009) Pituitary adenylate cyclase activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283–357. https://doi.org/10.1124/pr.109.001370
Wada Y, Nakamachi T, Endo K, Seki T, Ohtaki H, Tsuchikawa D, Hori M, Tsuchida M, Yoshikawa A, Matkovits A, Kagami N, Imai N, Fujisaka S, Usui I, Tobe K, Koide R, Takahashi H, Shioda S (2013) PACAP attenuates NMDA-induced retinal damage in association with modulation of the microglia/macrophage status into an acquired deactivation subtype. J Mol Neurosci 51(2):493–502. https://doi.org/10.1007/s12031-013-0017-5
Wang ZY, Alm P, Hakanson R (1995) Distribution and effects of pituitary adenylate cyclase-activating peptide in the rabbit eye. Neuroscience 69(1):297–308. https://doi.org/10.1016/0306-4522(95)00258-k
Waschek JA (2002) Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Dev Neurosci 24(1):14–23. https://doi.org/10.1159/000064942
Werling D, Banks WA, Salameh TS, Kvarik T, Kovacs LA, Vaczy A, Szabo E, Mayer F, Varga R, Tamas A, Toth G, Biro Z, Atlasz T, Reglodi D (2017) Passage through the ocular barriers and beneficial effects in retinal ischemia of topical application of PACAP1-38 in rodents. Int J Mol Sci 18(3):675. https://doi.org/10.3390/ijms18030675
Werling D, Reglodi D, Banks WA, Salameh TS, Kovacs K, Kvarik T, Vaczy A, Kovacs L, Mayer F, Danyadi B, Lokos E, Tamas A, Toth G, Zs B, Tamas A, Atlasz T (2016) Ocular delivery of PACAP1-27 protects the retina from ischemic damage in rodents. Invest Ophthalmol Vis Sci 57(15):6683–6691. https://doi.org/10.1167/iovs.16-20630
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O’Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY, Meta-Analysis for Eye Disease (META-EYE) Study Group (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556–564. https://doi.org/10.2337/dc11-1909
Ye D, Shi Y, Xu Y, Huang J (2019) PACAP attenuates optic nerve crush-induced retinal ganglion cell apoptosis via activation of the CREB-Bcl-2 pathway. J Mol Neurosci 68(3):475–484. https://doi.org/10.1007/s12031-019-01309-9
Zaltzman R, Alexandrovich A, Trembovler V, Shohami E, Gozes I (2005) The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Peptides 26:1520–1527. https://doi.org/10.1016/j.peptides.2005.03.014
Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, Brenneman DE, Gozes I (2001) Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 276(1):708–14. https://doi.org/10.1074/jbc.M007416200.
Zemlyak I, Manley N, Sapolsky R, Gozes I (2007) NAP protects hippocampal neurons against multiple toxins. Peptides 28(10):2004–2008. https://doi.org/10.1016/j.peptides.2007.08.004
Zeng HY, Green WR, Tso MO (2008) Microglial activation in human diabetic retinopathy. Arch Ophthalmol 126:227–232. https://doi.org/10.1001/archophthalmol.2007.65
Zeng XX, Ng YK, Ling EA (2000) Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci 17:463–471. https://doi.org/10.1017/s0952523800173122
Zhang XY, Hayasaka S, Chi Z-L, Cui H-S, Hayasaka Y (2005) Effect of pituitary adenylate cyclase activating polypeptide (PACAP) on IL-6, and MCP-1 expression in human retinal pigment epithelial cell line. Curr Eye Res 30:1105–1111. https://doi.org/10.1080/02713680500421444
Zheng Y, Zeng H, She H, Liu H, Sun N (2010) Expression of peptide NAP in rat retinal Müller cells prevents hypoxia-induced retinal injuries and promotes retinal neurons growth. Biomed Pharmacother 64(6):417–423. https://doi.org/10.1016/j.biopha.2010.01.016
Zusev M, Gozes I (2004) Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP Regul Pept 123(1–3):33–41. https://doi.org/10.1016/j.regpep.2004.05.021
Funding
National Research, Development and Innovation Fund NKFIH135457, 129190, National Brain Research Program NAP2017-1.2.1-NKP-2017-00002; MTA-TKI-14016; GINOP-2.3.2-15-2016-00050 “PEPSYS”; FIKP Program.
Author information
Authors and Affiliations
Contributions
A.G.D and G.M.: writing original draft preparation, V.D and D.R: writing—review and editing, G.M: visualization, V.D: supervision, D.R: funding acquisition. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no conflict of interest.
Consent for Publication
The authors agree to publication.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
D’Amico, A.G., Maugeri, G., Musumeci, G. et al. PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy. J Mol Neurosci 71, 1525–1535 (2021). https://doi.org/10.1007/s12031-020-01769-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-020-01769-4